IMARX THERAPEUTICS INC Form 10-Q/A December 30, 2009

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 10-Q/A Amendment No. 1

p Quarterly report pursuant to Section 13 or 15(c) For the Quarterly Period ended March 31, 2009	d) of the Securities Exchange Act of 1934							
O Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  For the Transition Period from to  Commission File Number 001-33043								
ImaRx Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter)								
(23.000 1 (mino 01 200 gibit min mi Sperimen in 105 Charter)								
Delaware	86-0974730							
(State or Other Jurisdiction of	(I.R.S. Employer							
Incorporation or Organization)	<b>Identification No.)</b>							
ImaRx Therapeutics, Inc.								
c/o Stoel Rives LLP								
201 S. Main Street, Suite 1100								
Salt Lake City, Utah	84111							
(Address of Principal Executive Offices)	(Zip Code)							
(801) 578-69	<sup>-</sup>							
(Registrant s Telephone Numbe	er, Including Area Code)							

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. YES b NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES o NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company b

### Edgar Filing: IMARX THERAPEUTICS INC - Form 10-Q/A

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO b

The number of shares outstanding of each of the issuer s classes of common stock, as of the latest practicable date is as follows:

Class

Outstanding at December 29, 2009

Common Stock \$0.0001 par value

11,665,733

#### **EXPLANATORY NOTE**

ImaRx Therapeutics, Inc. (the Company ) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 (the Report ) for the sole purpose of amending Exhibit Nos. 31.1 and 31.2 to include the introductory language of paragraph 4 and the language of paragraph 4(b) of Item 601(b)(31) Regulation S-K Except as described above, no other changes are made to Report, and this Form 10-Q/A does not amend, update or change any other Item or the disclosures in the Report in any way. This Form 10-Q/A does not reflect events occurring after the filing of the Report or modify or update those disclosures, including any exhibits to the Report, affected by subsequent events.

Item 6. Exhibits. Exhibits

Exhibit		Filed		Incorporated by Reference Exhibit		ce
No.	Exhibit Title	Herewith	Form	No.	File No.	Filing Date
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer	X				
31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer	X				
32	Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Principal Financial and Accounting Office		10-Q	32	001-33043	May 14, 2009
		2				

#### Edgar Filing: IMARX THERAPEUTICS INC - Form 10-Q/A

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10Q/A to be signed on its behalf by the undersigned, thereunto duly authorized.

#### IMARX THERAPEUTICS, INC.

Date: December 29, 2009 By: /s/ RICHARD LOVE

Richard Love,

Chairman of the Board

(Principal Executive Officer and Principal

Financial Officer)

3

# Edgar Filing: IMARX THERAPEUTICS INC - Form 10-Q/A

## **EXHIBIT INDEX**

#### **Exhibit Index**

				<b>Incorporated by Reference</b>			
Exhibit		Filed		Exhibit			
No.	Exhibit Title	Herewith	Form	No.	File No.	Filing Date	
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer	X					
31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer	X					
32	Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Principal Financial and Accounting Officer		10-Q	32	001-33043	May 14, 2009	